Utah Medical Products, Inc. - Common Stock (UTMD)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — May 17, 2026Investment Snapshot
- Trading 18% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 9.0% — below-average profitability
- Revenue declining 6% annually
Utah Medical Products, Inc. - Common Stock (UTMD) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NASDAQ , with a market capitalisation of $202 million . Key value metrics: P/E ratio 18.6, P/B ratio 1.68, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Utah Medical Products, Inc. - Common Stock — Fundamental Analysis Summary
Utah Medical Products, Inc. - Common Stock (UTMD) is currently trading 18% above its Graham Number of $53.83, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 18.6x.
On financial health, UTMD shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 9.0% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.00.
StockPik's composite Value Score for UTMD is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
UTMD reports a solid gross margin of 57.9% (sector average: 40.1%) and a strong operating margin of 30.7%.
UTMD shows revenue declining at 6% year-over-year, with earnings declining at 19%.